Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$11.74 USD

11.74
1,452,260

+1.16 (10.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.74 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2

by Zacks Equity Research

Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.

Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates

by Zacks Equity Research

Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.

Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.

Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark

by Zacks Equity Research

Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.

Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.

Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates

by Zacks Equity Research

Emergent's (EBS) earnings miss estimates in the second quarter of 2019 while revenues surpass the mark.

Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss

by Zacks Equity Research

Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.

IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus

by Zacks Equity Research

IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.

Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acorda (ACOR) delivered earnings and revenue surprises of 48.11% and 91.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales

by Zacks Equity Research

Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.

Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View

by Zacks Equity Research

Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.

Amgen (AMGN) Catches Eye: Stock Jumps 5.7%

by Zacks Equity Research

Amgen (AMGN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance

by Zacks Equity Research

Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.

Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2

by Zacks Equity Research

Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.

Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View

by Zacks Equity Research

The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.

Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

Analysts Estimate Acorda Therapeutics (ACOR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acorda Therapeutics (ACOR) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Acorda Therapeutics (ACOR) closed at $6.82, marking a +0.89% move from the previous day.

Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Alexion (ALXN) beats both earnings and sales estimates in the second quarter of 2019 and raises 2019 guidance.

Horizon's NDA for Procysbi New Dosage Form Accepted by FDA

by Zacks Equity Research

The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.

Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study

by Zacks Equity Research

Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.

FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug

by Zacks Equity Research

The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.

Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

by Zacks Equity Research

Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.

ObsEva Ends Recruitment in Second Uterine Fibroids Study

by Zacks Equity Research

ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.

Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.